Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1.

Creator(s)

Kelly E. Faulk
John A. Kairalla
Emily Hibbitts
Janel Long-Boyle
Meenakshi Devidas
Amanda August, Children's Mercy Kansas CityFollow
Lia Gore
Elizabeth Raetz
Stephen P. Hunger
Mignon L. Loh
David T. Teachey
Patrick Brown
Erin H. Breese
Rishi S. Kotecha
Erin Guest

Document Type

Letter to the Editor

Publication Date

1-13-2026

Identifier

DOI: 10.1182/bloodadvances.2025017013; PMCID: PMC12804146

Journal Title

Blood Adv

Volume

10

Issue

1

First Page

70

Last Page

74

PubMed ID

40991382

Comments

Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution.

Publisher's Link: https://ashpublications.org/bloodadvances/article/10/1/70/547437/Age-based-pegaspargase-dosing-is-safe-and-achieves

Recommended Citation

Faulk KE, Kairalla JA, Hibbitts E, et al. Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1. Blood Adv. 2026;10(1):70-74. doi:10.1182/bloodadvances.2025017013